Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Refractory Autoimmune Encephalitis
NCT02714959Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2016
- Primary completion
- Jun 2019
- Modality
- Cytokines & Interferons
01
Overview
A Phase 2 trial of aldesleukin in Autoimmune Encephalitis (AE), sponsored by Seoul National University Hospital. Started Mar 2016; status: completed.
02
Drugs
aldesleukin
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT02714959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02714959.